Top Midday Decliners

01:55 PM EST, 11/09/2026 (MT Newswires) -- Faeth Therapeutics' (FTH) topline clinical results from a phase 2 trial of Piktor plus paclitaxel in patients with advanced endometrioid endometrial cancer showed a confirmed objective response rate of 33% in efficacy-evaluable patients and a disease control rate of 83%, it said Monday. Shares plunged 43% as intraday trading volume climbed to over 2.3 million from a daily average of about 370,000. Abeona Therapeutics (ABEO) acquired APT-1011, a drug candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals for $20 million in common stock, it said Monday. Shares sank 34% as intraday trading volume soared to over 8.5 million from a daily average of roughly 1.4 million. Nvidia (NVDA) launched an independent investigation following reports that CEO Jensen Huang may have been the target of a foreign intelligence operation after the executive admitted to having an extramarital affair. Shares dropped 5.2%, with intraday trading volume rising to over 330 million, from a daily average of about 117.3 million.